TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06448663

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin, fructooligosaccharides, inulin
Description: The first round supplementation will be administered for 3-month period (i.e. 12 weeks). One dose/day (2g sachet) is intended to be administered orally once a day after dissolving in water.~At the scheduled visits/phone contacts \[i.e., baseline, 12 weeks, and 16 weeks (post washout)\], seizure frequency and entity of the critical episodes will be recorded. Gut microbiome characterization, clinical scales and dietary intake will be assessed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin, sodium butyrate, fructooligosaccharides, inulin
Description: The second round supplementation will be administered for 3-month period (i.e. 12 weeks). For participants weighing \<30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in water. For participants weighing ≥30 kg, a 4 g dose (i.e., 4 g sachets) is intended to be administered orally twice a day (12h interval) after dissolving in water.~At the scheduled visits/phone contacts \[i.e., 28 weeks and 32 weeks (post washout)\], seizure frequency and entity of the critical episodes will be recorded. Gut microbiome characterization, clinical scales and dietary intake will be assessed.
Study: NCT05824910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program (virtual/remote)
Description: Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions
Study: NCT05229133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEAR
Description: FEMTO LDV Z8 Surgical Laser is intended for use in Corneal Lenticule Extraction for Advanced Refractive correction (CLEAR), also called Curved Lamellar Resection (CLR), for the reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude.
Study: NCT05901870

Intervention type: OTHER
Intervention: Questionnaire administration
Description: All study participants will be surveyed with the questionnaire, which includes such instruments as EQ-5D-3L and WG-SS, to assess their health-related quality of life, health-related behavior, and health care utilization indicators.
Study: NCT06018285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Approach to Reducing Risk of Suicide in Primary Care
Description: Intervention consists of implementation of clinical pathway for youth suicide risk
Study: NCT06493799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAENNEC (Human Placenta Hydrolysate) IV
Description: Intravenous Injection
Study: NCT05315063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Training
Description: Once achieved, this flexed hip position will be held for 5 seconds. This procedure will be repeated 6 times with no rest between repetitions
Study: NCT06493799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAENNEC (Human Placenta Hydrolysate) SC
Description: Subcutaneous Injection
Study: NCT05315063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Training
Description: Once achieved, this flexed hip position will be held for 5 seconds. This procedure will be repeated 6 times with no rest between repetitions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique (PIR)
Description: The participant will be asked to resist the movement with no more than 25% of strength. The contraction will be held for 7-10 seconds followed by complete relaxation of the limb.~On exhalation, the knee joint will be straightened (extended) towards its new barrier and through that barrier a stretch was applied and maintained for 30 seconds.3 repetitions of this process will be done

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique (PIR)
Description: The participant will be asked to resist the movement with no more than 25% of strength. The contraction will be held for 7-10 seconds followed by complete relaxation of the limb.~On exhalation, the knee joint will be straightened (extended) towards its new barrier and through that barrier a stretch was applied and maintained for 30 seconds.3 repetitions of this process will be done
Study: NCT06474169

Intervention type: OTHER
Intervention: 1 blood sample for each participant
Description: Blood sample for cohort n°1 and n°2 (collection during a peripheral venous blood sample, part of the standard of care for this disease) :~1 blood sample for each patient 28mL of blood (4 tubes, 7mL per tube)~Blood samples for cohort n°3 (collection during blood donation at Etablissement Français du Sang) :~1 blood sample for each healthy donor 14mL of blood (2 tubes, 7mL per tube)

Intervention type: OTHER
Intervention: 1 blood sample for each participant
Description: Blood sample for cohort n°1 and n°2 (collection during a peripheral venous blood sample, part of the standard of care for this disease) :~1 blood sample for each patient 28mL of blood (4 tubes, 7mL per tube)~Blood samples for cohort n°3 (collection during blood donation at Etablissement Français du Sang) :~1 blood sample for each healthy donor 14mL of blood (2 tubes, 7mL per tube)
Study: NCT05817201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg day7 and day 28，every 3 weeks 1month after radiotherapy，until progression or 1 years or intolerant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur
Description: Tegafur 70mg/m2/day day 1 to day 14，and day 29 to day42.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: PGTV 54Gy/2.16Gy/25F/5W, PTV 45Gy/1.8Gy/25F/5W

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: PGTV 54Gy/2.16Gy/25F/5W, PTV 45Gy/1.8Gy/25F/5W
Study: NCT06432777

Intervention type: OTHER
Intervention: Characteristics of patients and Campylobacter bacteraemia episodes
Description: Variables: characteristics of the patients (demographic characteristics; characteristics of immunodeficiency: diagnosis, immunoglobulin dosage, white cells count etc.; chronic inflammatory bowel disease \[IBD\]), the bacteria (species, antimicrobial susceptibility) and the infection (clinical presentation, evolution, treatment received)
Study: NCT04813510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture treatment
Description: Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) once a day for seven days. AfterDeqi, electroacupuncture stimulation apparatus(HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture treatment
Description: Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints).. Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group
Study: NCT05401071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Regimen with Rifapentine 10mg/kg
Description: rifapentine 10mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Regimen
Description: During the intensive phase, rifampicin ≤55kg 450mg daily, 55-71kg 600mg daily, \>71kg 750mg daily; isoniazid ≤55kg 225mg daily, 55-71kg 300mg daily, \>71kg 375mg daily; pyrazinamide ≤55kg 900mg daily, 55-71kg 1200mg daily, \>71kg 1600mg daily; ethambutol ≤55kg 825mg daily, 55-71kg 1100mg daily, \>71kg 1375mg daily; All treatment is taken orally.~During the continuation phase, rifampicin ≤50kg 450mg daily, \>50kg 600mg daily; isoniazid 300mg daily; All treatment is taken orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Regimen with Rifapentine 15mg/kg
Description: rifapentine 15mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Regimen with Rifapentine 20mg/kg
Description: rifapentine 20mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
Study: NCT06111248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Staff training on the use of surgical plethysmographic index (SPI) state entropy (SE) and train-of-four (TOF) intraoperative monitors and AoA software.
Study: NCT05420896

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Upper cervical spine mobilization Posterior-anterior mobilization of the fifth cervical vertebra Suboccipital inhibition Suboccipital mobilization Trigger point application to my masseter, temporal and sternocleidomastoid muscles Intraoral and extraoral myofascial release Intraoral sphenopalatine ganglion technique TMJ mobilization Massage for chewing muscles The 45-minute treatment program, which includes applications including the techniques above, will be applied to the patients randomly assigned to the study group once a week for a total of 4 weeks.The changes in muscle activity of the masseter and anterior temporalis bilaterally will be recorded with EMG.
Study: NCT04402593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Heidelberg Model of Neuro-Music Therapy
Description: 6 sessions, 2 sessions a week including the following interventions: resonance training, music relaxation, Intonation Training and session review/homework.
Study: NCT05771480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + oxaliplatin
Description: Gemcitabine + oxaliplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + carboplatin
Description: Gemcitabine + carboplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + cisplatin + S-1
Description: Gemcitabine + cisplatin + S-1 as background gemcitabine-based chemotherapy every 2 weeks (i.e, 4 cycles of durvalumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + S-1
Description: Gemcitabine + S-1 as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + cisplatin + albumin-bound paclitaxel
Description: Gemcitabine + cisplatin + albumin-bound paclitaxel as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
Study: NCT05233995

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Damage Control Surgery
Description: Delayed anastomosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Damage Control Surgery
Description: Delayed anastomosis
Study: NCT06627764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SER Familia
Description: SER Familia is a six-session intervention co-developed and delivered by community health workers (CHWs) that uses strategies to reduce acculturative stress, promote resilience, improve parent-child and family level health, while simultaneously helping families maintain strong social networks and better navigate community resources to address social determinants of health (SDOH).
Study: NCT06064721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buerger-Allen Exercise
Description: Buerger-Allen exercise will be taught by researcher and perform by patient at home twice a day
Study: NCT05564195

Intervention type: DIAGNOSTIC_TEST
Intervention: Postoperative cognitive function
Description: Digital cognitive tests - Mindmore-P, will be used to assess neurocognitive capacity and includes tests of verbal episodic memory, executive functions, visuospatial function and attention. The cognitive tests are self-administered on a touch screen tablet (10.1 20-30 min Windows). The Mindmore-P is a web-application running on a full-screen Chrome browser. The test is administered by using a capacitive touchscreen with features that record detailed information such as timing, pauses, and lifting of finger from the touchscreen. Speech recognition is used in the screening of verbal memory and language.
Study: NCT05618067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing exercise training
Description: Participants will engage in weekly breathing exercises. They will be trained once a week for 4 weeks, and will use an app called Inner Balance and an device called Firstbeat Bodyguard 3 to track data about their hearts while practicing the exercises at home for 10 minutes a day, twice a day, once before bedtime.
Study: NCT06544954

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried grape powder
Description: 40 grams powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried grape powder
Description: 40 grams powder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo powder
Description: 40 grams powder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo powder
Description: 40 grams powder
Study: NCT05660421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Given by mouth or by vein

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Procedure
Description: Undergo endoscopic procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Undergo skin biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool
Study: NCT04303663

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fibular Plate
Description: ORIF with Plating

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibular Nail
Description: CRIF +/- ORIF with Fibular nail
Study: NCT06331338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Cycle for Person-Centered Glycemic Management
Description: It is defined as a purposefully designed holistic care intervention that improve self-management .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional diabetes self-management education
Description: Traditional diabetes self-management education content focuses more on teaching relevant knowledge and some skills.
Study: NCT04805411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: IL-4Rα monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: IL-4Rα monoclonal antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05362786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived mesenchymal stem cells (MSC)
Description: Two intravenous infusions delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 100x10\^6 cells at day 0 and day 84

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived mesenchymal stem cells (MSC)
Description: Single intravenous infusion delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 200x10\^6 cells at day 0
Study: NCT06132867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib oral solution
Study: NCT06198257

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spider cage
Description: 5 days a week for an hour/daily with conventional exercises. Assisted sit to stand (10 to 15---15 to 20) Assisted weight shift (10 to 15---15 to 20) Assisted trunk rotation (10 to 15---15 to 20) Hip Abd / Add. exercises (10 to 15---15 to 20) Bridge exercises (10 to 15---15 to 20)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: modified suits therapy
Description: 5 days a week for an hour/daily with conventional exercises. Assisted sit to stand (10 to 15---15 to 20) Assisted weight shift (10 to 15---15 to 20) Assisted trunk rotation (10 to 15---15 to 20) Hip Abd / Add. exercises (10 to 15---15 to 20) Bridge exercises (10 to 15---15 to 20)
Study: NCT06376149

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: M3 Intervention group
Description: The M3© program offered online concurrently for parents and children (4-12 years of age). Each parent session is 90 minutes long, and each child session is 60 minutes long. Parents and children learn similar concepts, at developmentally appropriate levels.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: M3 Waitlist Group
Description: The M3© program offered online concurrently for parents and children (4-12 years of age). Each parent session is 90 minutes long, and each child session is 60 minutes long. Parents and children learn similar concepts, at developmentally appropriate levels.
Study: NCT05782296

Intervention type: DEVICE
Intervention: TrueLabor
Description: Non invasive monitoring device
Study: NCT06294028

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adverse events collection
Description: Collection of deaths from any cause, hospitalizations or emergency consultations for any event related to ventricular arrhythmia or its treatment (recurrence of ventricular tachycardia or complication linked to the defibrillator or crossover from one group to another)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adverse events collection
Description: Collection of deaths from any cause, hospitalizations or emergency consultations for any event related to ventricular arrhythmia or its treatment (recurrence of ventricular tachycardia or complication linked to the defibrillator or crossover from one group to another)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life questionnaire EQ-5D-5L
Description: Questionnaire on the patient's quality of life and health in 6 questions: on mobility, the person's autonomy, current activities, pain, anxiety. Answers range from no problem to unable and 5 possible answers to each question.~The last question concerns the patient's health, the patient must rate his or her health on a scale of 0 to 100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire EQ-5D-5L
Description: Questionnaire on the patient's quality of life and health in 6 questions: on mobility, the person's autonomy, current activities, pain, anxiety. Answers range from no problem to unable and 5 possible answers to each question.~The last question concerns the patient's health, the patient must rate his or her health on a scale of 0 to 100

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical-economic evaluation
Description: Collection of expenses incurred by the care of patients in each arm will be collected over a period of 36 months.~Direct medical and non-medical costs as well as costs related to absences from the workplace will be included in the analysis. Healthcare consumption will be collected using the National Health Data System (SNDS).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical-economic evaluation
Description: Collection of expenses incurred by the care of patients in each arm will be collected over a period of 36 months.~Direct medical and non-medical costs as well as costs related to absences from the workplace will be included in the analysis. Healthcare consumption will be collected using the National Health Data System (SNDS).
Study: NCT06205030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-diabetic herbal drug
Description: All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anti-diabetic herbal drug
Description: All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
Study: NCT06132867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablet
Study: NCT06627699

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: Post-Market Surveillance of the Freedom Total Knee System for Primary TKA
Study: NCT05674513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal acetate
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes after 1 dose of Ulipristal acetate 30mg in individuals with and without active CYP3A5 alleles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal acetate
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes after 1 dose of Ulipristal acetate 30mg in individuals with and without active CYP3A5 alleles
Study: NCT06742827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention based on information and communication technologies.
Description: will be carried out through a mobile application, which will be installed on each person's device, as well as short text messages will be sent and counseling will be available 24/7. The contents of the application will be educational and will be elaborated framed in the following components: understanding of the disease and the consequences of not adhering (comprehensibility) to the treatment, maintaining a balance between the psychosocial resources that the patient has and the demands that the disease places on them (manageability), and the involvement of the person in decision making and the sense of continuing to adhere to hemodialysis treatment (meaningfulness).
Study: NCT06742255

Intervention type: DRUG
Intervention: Stellate Ganglion Block
Description: Stellate ganglion block is an injection of local anesthetic at the level of the neck to target the stellate ganglion, a sympathetic ganglion to interrupt abnormal autonomically-mediated pain in patients resistant to medical treatment